Delivery Order SPE2DB22D3401-SPE2DB25FT2FH

Award Date 2/24/25
Potential Completion Date 2/25/25
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,554.12 firm-fixed-price contract is for the supply of GVOKE HYPOPEN 1-PK 1 MG/0.2 ML 0.2ML, a medical product. The contract has an ultimate completion date of February 11, 2025. This award is under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,400.12, is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999 and running through November 2026. This IDC enables the government to efficiently procure a comprehensive range of pharmaceutical products and medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML medical products. The Firm Fixed Price Delivery Order, valued at $1,949.31, has a completion date of December 18, 2024. This award is a part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,960.12, is for the delivery of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML, a medication used for the treatment of hypoglycemia. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award, valued at $3,912.94, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The award is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,468.52 delivery order contract is for the supply of GVOKE HYPOPEN 2PK 0.5MG/0.1 ML 0.1ML, a medical product. The contract has a firm fixed-price pricing type and a completion date of May 9, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a $14,426.64 delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the supply of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML, a medical product, with a completion date of February 7, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, for the delivery of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML medical supplies. The award, valued at $2,109.27, is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, worth up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,352.73 firm fixed-price delivery order is for the supply of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML, a medical product, with a completion date of February 12, 2025. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery...
This is a $4,159.94 delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for GVOKE HYPOPEN 2PK 0.5MG/0.1 ML 0.1ML, a medical product, with a period of performance through January 21, 2025. This is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
  • SPE2DB22D3401
    Indefinite Delivery Contract
  • SPE2DB22D3401-SPE2DB25FT2FH
    Delivery Order

This federal contract award, valued at $1,425.93, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML 0.2ML medical products. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific delivery order does not have a set-aside designation, indicating open competition. The contract has a completion date of February 25, 2025.

Generated 6/1/25, 3:20 AM